These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15193684)

  • 1. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
    Sposito AC; Lemos PA; Santos RD; Hueb W; Vinagre CG; Quintella E; Carneiro O; Chapman MJ; Ramires JA; Maranhão RC
    J Am Coll Cardiol; 2004 Jun; 43(12):2225-32. PubMed ID: 15193684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors?
    Brinton EA; Nanjee MN; Hopkins PN
    J Am Coll Cardiol; 2004 Jun; 43(12):2233-5. PubMed ID: 15193685
    [No Abstract]   [Full Text] [Related]  

  • 3. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease.
    Sposito AC; Ventura LI; Vinagre CG; Lemos PA; Quintella E; Santos RD; Carneiro O; Ramires JA; Maranhão RC
    Atherosclerosis; 2004 Oct; 176(2):397-403. PubMed ID: 15380465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of chylomicrons in patients with congenital lipoatrophic diabetes: a study with emulsion models of chylomicrons.
    Wajchenberg BL; Amâncio RF; Santomauro AT; Maranhão RC
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):347-52. PubMed ID: 15355451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease.
    Solymoss BC; Bourassa MG; Lespérance J; Levesque S; Marcil M; Varga S; Campeau L
    Coron Artery Dis; 2003 May; 14(3):207-12. PubMed ID: 12702923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chylomicron metabolism is markedly altered in systemic lupus erythematosus.
    Borba EF; Bonfá E; Vinagre CG; Ramires JA; Maranhão RC
    Arthritis Rheum; 2000 May; 43(5):1033-40. PubMed ID: 10817556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.
    Krecki R; Drozdz J; Szcześniak P; Orszulak-Michalak D; Krzemińska-Pakuła M
    Kardiol Pol; 2008 Nov; 66(11):1173-80; discussion 1181-2. PubMed ID: 19105094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.
    März W; Scharnagl H; Winkler K; Tiran A; Nauck M; Boehm BO; Winkelmann BR
    Circulation; 2004 Nov; 110(19):3068-74. PubMed ID: 15505088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of chylomicron-like emulsions in carriers of the S447X lipoprotein lipase polymorphism.
    Almeida KA; Schreiber R; Amâncio RF; Bydlowski SP; Debes-Bravo A; Issa JS; Strunz CM; Maranhão RC
    Clin Chim Acta; 2003 Sep; 335(1-2):157-63. PubMed ID: 12927697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne.
    De Marchi MA; Maranhão RC; Brandizzi LI; Souza DR
    Arch Dermatol Res; 2006 Mar; 297(9):403-8. PubMed ID: 16429299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol.
    DeFaria Yeh D; Freeman MW; Meigs JB; Grant RW
    Am J Cardiol; 2007 Jan; 99(1):1-4. PubMed ID: 17196452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease.
    Inoue T; Kotooka N; Morooka T; Komoda H; Uchida T; Aso Y; Inukai T; Okuno T; Node K
    Am J Cardiol; 2007 Aug; 100(4):569-74. PubMed ID: 17697807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.